HWM
ALNY icon

HB Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

HB Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Sell
1,824
-171
-9% -$51.6K ﹤0.01% 1053
2026
Q1 		$660K Buy
1,995
+294
+17% +$100K ﹤0.01% 842
2025
Q4 		$677K Buy
1,701
+225
+15% +$99.6K ﹤0.01% 766
2025
Q3 		$673K Buy
1,476
+607
+70% +$247K ﹤0.01% 731
2025
Q2 		$284K Buy
869
+98
+13% +$27.1K ﹤0.01% 966
2025
Q1 		$208K Buy
+771
New +$198K ﹤0.01% 1125

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HB Wealth Management's ALNY Position: Q2 2026 in Review

HB Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 8.6% in Q2 2026, selling an estimated $51.6K and leaving 1,824 shares worth $549K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

HB Wealth Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $677K in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • HB Wealth Management held 1,824 shares of Alnylam Pharmaceuticals worth $549K as of Q2 2026.
  • HB Wealth Management sold 171 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $51.6K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1053 holding.
  • HB Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • HB Wealth Management's Alnylam Pharmaceuticals position peaked at $677K in Q4 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.